Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data FENNEC PHARMACEUTICALS INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0
0
0.17
1.77
23.8
47.5
44.6
Cost of revenue
0.09
1.26
Gross profit
1.45
20
Research and development
0.47
1.94
5.01
5.61
5.11
4.98
3.53
0.06
0.31
0.25
Selling and marketing
2.79
12.1
18.4
18.6
General and administrative
2.4
5.02
5.4
7.4
13
12.2
17.7
20.6
23.1
28.3
Operating expenses
13
18.1
17.2
24
34
45
50.9
Operating income
-2.87
-6.95
-10.4
-13
-17.9
-17.2
-22.6
-12.8
2.57
-6.28
Interest expense
3.39
4.07
2.08
Interest income
0.44
1.68
0.79
Other non-operating income
0.08
-0.1
0.52
0.23
-0.22
-0.12
-1.13
-3.27
-2.64
-3.35
Pre-tax income
-2.79
-7.05
-7.7
-9
-8.78
-9.12
-10.5
-16
-0.07
-9.64
Income tax
0
0
0
0
0
0
0
0.37
0.11
Net income
-2.79
-7.05
-9.89
-12.8
-18.1
-17.3
-23.7
-16
-0.44
-9.74
EPS, basic
-0.22
-0.47
-0.52
-0.64
-0.76
-0.67
-0.90
-0.60
-0.02
-0.34
EPS, diluted
-0.22
-0.47
-0.52
-0.64
-0.76
-0.67
-0.90
-0.60
-0.02
-0.34
Shares, basic (weighted)
12.8
15
18.9
19.9
0.02
26
26.3
26.6
27.3
28.6
Shares, diluted (weighted)
12.8
15
18.9
19.9
0.02
26
26.3
26.6
27.3
28.6
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
3.93
28.3
22.8
13.7
30.3
21.1
23.8
13.3
26.6
36.8
Other current assets
0
0.01
0
0.01
0.28
0.25
0.06
0.04
0.47
1.73
Total current assets
28.4
23
13.9
31.4
22.4
26.7
26.9
44.1
67
Other non-current assets
0.82
0.82
0.72
Total assets
3.97
28.4
23
14.1
31.4
22.4
26.9
26.9
44.9
70.6
Accounts payable
0.24
0.86
1.03
1.61
1.57
0.78
2.39
3.78
3.24
4.64
Accrued liabilities
0.13
0.62
0.61
0.66
0.78
0.88
2.22
3.75
3.43
5.64
Deferred revenue
0.25
0.25
Total current liabilities
0.4
1.64
1.64
2.27
2.35
1.65
4.61
7.55
6.92
10.5
Long-term debt
5
Lease liabilities
0
Total liabilities
0.4
1.64
1.64
2.27
2.35
6.64
29.5
38.5
50.8
35.1
Total debt
5
24.9
30.9
19.3
Paid-in capital
42.1
43.8
44.9
48.3
49.2
53.2
56.8
62.1
67
73.7
Retained earnings
-114
-121
-131
-144
-162
-179
-203
-219
-220
-229
Other comprehensive income
1.24
1.24
1.24
1.24
1.24
1.24
1.24
1.24
1.24
1.24
Shareholders' equity
3.57
26.8
21.3
11.9
29.1
15.8
-2.57
-11.6
-5.87
35.5
Total equity
3.57
26.8
21.3
11.9
29.1
15.8
-2.57
-11.6
-5.87
35.5
Total liabilities and equity
3.97
28.4
23
14.1
31.4
22.4
26.9
26.9
44.9
70.6
Shares outstanding
13.6
18.4
19.9
19.9
26
26
26.4
27
27.5
34.2
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-2.79
-7.05
-9.89
-12.8
-18.1
-17.3
-23.7
-16
-0.44
-9.74
Stock-based compensation
0.62
1.52
1.83
2.67
2.79
3.75
4.09
5.35
5.06
7.03
Change in receivables
-1.55
-7.27
-7.87
-12.4
Change in inventory
-0.58
-1.58
0.58
-1.28
Change in payables
-0.05
0.61
0.18
0.58
-0.04
-0.79
1.61
1.39
-0.54
1.39
Cash from operations
-2.12
-3.64
-7.83
-9.06
-15.6
-14.2
-18.1
-17.1
27
-12.5
Cash from investing
0
0
0
Debt issued
5
24.9
5
Debt repaid
-5
-13
-19.5
Stock issued
5
27.4
0
0
32
0.03
0.93
1.72
1.3
2.19
Cash from financing
5.11
28
2.35
-0.07
32.3
4.98
20.7
6.64
-13.6
22.6
Exchange rate effect
0
Net change in cash
2.98
24.3
-5.48
-9.13
16.7
-9.24
2.67
-10.5
13.4
10.2
Interest paid
3.82
4.16
Income taxes paid
0.75
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $10.61 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-1.9%
Operating income / revenue.
Net margin
-5.5%
Net income / revenue.
Operating cash flow margin
-3.4%
Cash from operations / revenue.
Return on equity (ROE)
-7.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-4.3%
Net income / average total assets.
Return on invested capital (ROIC)
-74.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
0.4%
Research and development expense / revenue.
Stock-based pay / revenue
12.7%
Stock-based compensation (from the cash flow statement) / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-6.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
193.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
204.7%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y
-344.6%
Operating income vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
-146.2%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Book value CAGR, 5y
4.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
57.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
37.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
17.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
4.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
2.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
313.3%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.85x
Current assets / current liabilities.
Quick ratio
3.33x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.33x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.63
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.06
Cash from operations / diluted weighted shares.
Book value per share
$1.21
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
6.27x
Market cap / revenue.
P/B
8.75x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
8.75x
Market cap / tangible book value, when positive.
EV/Sales
5.58x
Enterprise value / revenue.
Earnings yield
-0.9%
Net income / market cap (the inverse of P/E).
What was FENNEC PHARMACEUTICALS INC.'s revenue in fiscal 2025?
FENNEC PHARMACEUTICALS INC. reported revenue of $44.6M for fiscal 2025, 6.1% lower than the year before.
Was FENNEC PHARMACEUTICALS INC. profitable in fiscal 2025?
No. It reported a net loss of $9.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.